Hematologist
CION Cancer Clinics
Why haematology has so many clinical trials | CION Cancer Clinics
Blood cancers have many trials because they split into many small types, each driven by its own gene changes, and because blood and bone marrow make it easy to measure whether a medicine is working. Being offered a trial does not mean your case is hopeless. This page explains why trials are so common, how they work, who they may not suit and what to ask. At CION Cancer Clinics, our haematology team supports patients and families through treatment, cost questions and life at home.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Why are there so many trials for blood cancers?
- What makes blood cancers so suited to research?
- How does a new blood cancer medicine reach patients?
- Does being offered a trial mean treatment has failed?
- What do families believe about trials, and what is true?
- What do the words on a trial sheet mean?
- What can this page not tell you, and what should you ask?
- Common questions about blood cancer trials
The short answer
Why are there so many trials for blood cancers?
Blood cancers are split into many small types, and each one is driven by its own changes in the blood cells. Blood is also easy to sample and measure, so researchers can see quickly whether a new medicine is working. Together, those two facts make leukaemia, lymphoma and myeloma some of the most studied cancers in the world.
Why the number of types matters
Your report may name a subtype, a gene change and a risk group. Each can change which medicine is likely to help, and every new subgroup needs its own studies.
Why this is useful to know
If a haematologist mentions a trial, it does not mean your case is unusual or hopeless. In blood cancers, trials are a normal part of how treatment moves forward. Many of today's standard treatments were once trial medicines.
A trial is one option among several. Whether it suits you depends on your exact diagnosis, your past treatment and your general health.What drives it
What makes blood cancers so suited to research?
Four features come up again and again. None of them is true for every blood cancer, but most apply to the common ones.
Response is easy to measure
A blood test or a bone marrow sample shows how many cancer cells are left. Researchers do not have to wait months for a scan to change. That makes studies faster and clearer.
The cause is often a known gene change
Many blood cancers carry a specific change in the cell's genes. A medicine can be designed to block that one change, and a trial can test it only in people who carry it.
Common examples on reports
- BCR-ABL in chronic myeloid leukaemia
- FLT3 or NPM1 in acute myeloid leukaemia
The immune system can be redirected
Blood cancer cells carry clear markers on their surface. Antibodies, CAR-T cells and newer immune medicines use those markers as targets, and each new approach needs careful testing.
Many come back and need a next step
Some blood cancers respond well at first and return later. Each time that happens, doctors need another option. Trials in relapsed disease are how those next options are found.
Not sure whether this applies to you?
Ask an oncologistFrom lab to clinic
How does a new blood cancer medicine reach patients?
-
Laboratory and early testing
The medicine is studied on cancer cells and in the laboratory first. Only a small share of medicines that look promising here ever reach people.
-
Phase I: is it safe, and at what amount?
A small group of patients, often with cancer that has come back, receive the medicine. The main aim is to learn about safety and side effects, not to prove it works.
-
Phase II: does it seem to work?
A larger group with one specific blood cancer is treated. Doctors look at how many respond, and how well, using blood and marrow tests.
-
Phase III: is it better than today's standard?
The new treatment is compared with the current standard treatment. Patients are usually put into groups by chance, so the comparison is fair.
-
Approval and later follow-up
In India, the Central Drugs Standard Control Organisation decides on approval. Studies often continue afterwards to watch for rare or late side effects in a much wider group of people.
If a trial is mentioned
Does being offered a trial mean treatment has failed?
No. Trials are offered at every stage of blood cancer care, including at first diagnosis. Some trials compare two good first treatments. Others test whether a shorter or gentler course works just as well.
Who a trial may suit
A trial is worth asking about when your subtype has a known gene change that a new medicine targets. It is also worth asking about when the cancer has come back after standard treatment, or when standard options are limited for your type. You need to be well enough to travel for visits and attend extra tests.
Who a trial may not suit
Trials have strict entry rules. People with serious heart, kidney or liver problems, another active cancer, or an ongoing infection are often not eligible. It may also not suit someone who cannot reach the trial centre regularly. Being left out of a trial is not a judgement on your outlook. It usually means the study needs a very specific group.
Never stop, skip or change your current medicines because you hope to join a trial. Your treating team decides this with you.Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families believe about trials, and what is true?
"Joining a trial means being used as an experiment."
Every trial in India must be approved by an ethics committee and registered before it starts. You are told the aims, the known risks and your rights in writing. A research team also watches each person closely, often more closely than in routine care.
"Someone in a trial may get no treatment at all."
In blood cancer trials this is very uncommon. Most compare a new treatment with the standard one, or add a new medicine on top of standard care. If a dummy medicine is used, the information sheet will say so plainly.
"The newest medicine must be the stronger one."
That is exactly what the trial is trying to find out. Some new medicines turn out better, some the same, and some worse.
"Once you sign, you cannot leave."
You can leave a trial at any time, without giving a reason. Your doctors must continue to treat you. Leaving does not cost you your place in normal care.
On the information sheet
What do the words on a trial sheet mean?
- Informed consent
- Your written agreement to join, given only after the trial has been explained in a language you understand and your questions are answered.
- Randomised
- People are put into treatment groups by chance, like a coin toss. Neither you nor your doctor chooses the group.
- Eligibility criteria
- The rules on who can and cannot join, such as the exact subtype, past treatment and blood test results.
- Measurable residual disease (MRD)
- Very small numbers of cancer cells left after treatment, found only by sensitive laboratory tests. Many blood cancer trials use it to judge response.
- Ethics committee
- An independent group that checks the trial is fair and safe before it starts, and keeps checking while it runs.
Being straight with you
What can this page not tell you, and what should you ask?
This page cannot tell you whether a trial exists for your blood cancer right now, or whether you would be accepted. Open trials change month to month, and entry depends on details that only your full reports show.
Questions to take to your haematologist
Ask whether your subtype or gene change is being studied anywhere in India. Ask what the standard treatment would be, so you can compare. Ask how often you would need to travel, which costs the sponsor pays, and what happens after the trial ends.
How CION can help
CION does not run blood cancer trials itself. Our haematology team, led by Dr. Basudev Pokhrel, reviews your reports, discusses your case at a tumour board and helps you understand whether a trial is worth asking about. Where it is, we help you approach qualified trial centres with the right papers.
No page can tell you your own outlook. That depends on your subtype, your gene results, your age and your overall health.Questions we are asked
Common questions about blood cancer trials
Are blood cancer trials only for people with no other option?
No. Many trials enrol people at first diagnosis, comparing two reasonable ways to treat the same cancer. Others are for cancer that has come back. Your haematologist can tell you which kind, if any, fits your situation. Being offered one is not a sign that your doctors have run out of ideas.
Why does my report list so many gene tests?
Gene changes help decide which treatment is likely to work and how closely you need watching. They also decide which trials you could join, because many new medicines target one change only. Ask your doctor to explain each result in plain words and keep a copy of the full report.
Is a trial medicine safer or more risky than standard treatment?
Nobody knows fully in advance, which is the reason for the trial. Early studies give some idea of side effects, and the information sheet lists what is known so far. You are watched closely, and the trial can be stopped if problems appear. Ask what is known about the medicine in people like you.
Are Indian patients part of international blood cancer trials?
Yes. Many large studies include hospitals in India, alongside trials designed and run here. Every trial held in India has to be registered with the national trial registry and approved by an ethics committee. Your doctor can check whether an Indian site is taking new patients.
Can children with leukaemia join trials?
Yes. Much of the progress in childhood leukaemia came through trials, and many children are treated on study plans. A parent or guardian gives consent, and older children are asked for their own agreement too.
Will I have to pay to be in a trial?
The trial medicine and trial-only tests are usually paid for by the sponsor. Travel, stay and some routine care may not be. The information sheet should list this clearly. If anyone asks you for money just to get a place in a trial, treat it as a warning sign and speak to your doctor.
If the trial medicine works, can I keep taking it?
It depends on the trial. Some sponsors continue to provide the medicine after the study ends, and some do not. Ask about this before you sign, and ask what your treatment would be if the medicine is not approved or not available afterwards.
Does taking part change how my other doctors treat me?
You still need your usual care for other health problems. Tell every doctor you see that you are in a trial, and carry the trial contact card. Some common medicines can interact with trial medicines, so check with the trial team before starting anything new, including herbal or home remedies.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Clinical Trials Information for Patients and Caregivers
- Cancer Research UK — Find a clinical trial
- NHS — Clinical trials
- Leukemia & Lymphoma Society — Clinical trials
- ICMR — Clinical Trials Registry - India
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Finding a Blood Cancer Trial in IndiaWhere trials are listed and how to search themWill I Get a Placebo in a Blood Cancer TrialWhat randomisation and dummy medicines really meanCosts Covered and Not Covered in a TrialWhat the sponsor usually pays and what you may still payWithdrawing From a TrialYour right to leave, and what happens nextClinical Trials in HaematologyThe full guide to blood cancer trials
Talk to us
Wondering whether a trial is worth asking about?
Share your reports with us. Our haematology team will review them and help you understand your options, including whether to approach a trial centre.